Xentria Highlights New Episode Of Lifetime® TV’s “Behind The Mystery” Segment Of “The Balancing Act®” On Sarcoidosis
CHICAGO, DECEMBER 06, 2021--Xentria Inc., a biotech company focused on developing novel biologics to address unmet clinical needs, today highlighted a new sarcoidosis episode of The Balancing Act airing on Lifetime on a specialized, recurring segment devoted to rare and genetic diseases. The live segment, which aired at 7:30 a.m. ET this morning, follows the unique diagnosis and treatment journey of a sarcoidosis patient and provides clinical insights from Dr. Peter Sporn, Director of the Sarcoidosis Center of Excellence at Northwestern Medicine in Chicago, regarding this rare and difficult to treat disease. The episode will be rebroadcast on December 14th, 2021 at 7:30 a.m. (ET/PT) on Lifetime TV.
“We look forward to continuing to amplify patient stories and broadening perceptions of this and other rare conditions to help connect more patients with effective and accessible care options.”
“We are pleased to partner with “The Balancing Act®” on their “Behind the Mystery” segment on Lifetime TV to highlight sarcoidosis, given our commitment to raising awareness of this rare and burdensome disease,” said Thomas Shea, President of Xentria. “We look forward to continuing to amplify patient stories and broadening perceptions of this and other rare conditions to help connect more patients with effective and accessible care options.”
To view the segment and hear the story, visit https://thebalancingact.com/category/behind-the-mystery/.
Xentria is a proud sponsor of the production of this segment.
Xentria, whose name stems from the word “centrality” was founded in 2020 and is an innovative biopharmaceutics company whose primary focus is to build an expansive product pipeline of cost-effective and efficacious biologics to address critical unmet need for patients suffering from rare diseases, immunologic, metabolic, and musculoskeletal disorders, as well as oncology. Headquartered in Chicago, with partners in Israel and China, the company is dedicated to research and development, clinical science, manufacturing, and commercialization and driven to treat the clinical and social burdens of diseases while fostering sustainable growth.
To learn more about Xentria visit www.xentria.com.
About “The Balancing Act®”
“The Balancing Act®” is a morning show created and produced by BrandStar that offers sensible solutions and essential information in a fun, entertaining format; providing resources to help people do life better. “The Balancing Act” features everything from delicious recipes, style makeovers and dream getaways to parenting tips and the latest news in health and wealth. Tune in to “The Balancing Act” weekdays at 7:30 a.m. (ET/PT) on Lifetime® and find all previously aired episodes on TheBalancingAct.com.
Sarcoidosis is a chronic, multisystem inflammatory disorder of unknown etiology that is characterized by the presence of noncaseating epithelioid granulomas, accompanied by infiltration of mononuclear cells and destruction of microarchitecture. The disease can affect the skin, eyes, heart, and central nervous system, and >90% of cases involve the lungs. Symptoms range from asymptomatic to severe—including respiratory insufficiency, blindness, neurological disease, and cardiac death. While medications for systemic organ involvement often control this disease, some patients fail to respond to initial treatments and require additional targeted therapy, resulting in significant costs and treatment burdens. This disease presents a significant unmet medical need and a very important area of research and development for Xentria.
646 250 0050